Early trial tests drug cocktails to target advanced cancers
NCT ID NCT03065387
Summary
This early-stage study is testing the safety and best doses of a drug called neratinib when given with one of three other drugs (everolimus, palbociclib, or trametinib). It is for adults with advanced solid tumors that have specific genetic mutations and have stopped responding to standard treatments. The goal is to see if these combinations can better control cancer growth by blocking different pathways that tumors use to survive.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.